Stemgen Effective For PBPC Mobilization, Not For Aphereses Reduction
Executive Summary
Amgen's Stemgen data support an indication for the stimulation of peripheral blood progenitor cells for autologous stem cell transplants in cancer patients, but not for reduction in time to neutrophil engraftment or reduction in leukaphereses, FDA's Biological Response Modifiers Advisory Committee agreed July 30.